OptimizeRx (NASDAQ:OPRX) Receives "Market Outperform" Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX - Free Report) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

A number of other analysts have also commented on OPRX. B. Riley lowered their target price on shares of OptimizeRx from $17.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, December 24th. Roth Mkm restated a "buy" rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Lake Street Capital reiterated a "buy" rating and set a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, Stephens initiated coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.50 price target for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, OptimizeRx presently has an average rating of "Moderate Buy" and an average price target of $9.06.

OptimizeRx Trading Up 2.5 %

Shares of OPRX traded up $0.14 during trading hours on Thursday, hitting $5.66. 127,130 shares of the stock traded hands, compared to its average volume of 155,105. The business has a fifty day moving average of $5.24 and a 200-day moving average of $6.50. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $104.26 million, a PE ratio of -4.26 and a beta of 1.38. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65.

Insiders Place Their Bets

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the acquisition, the chief executive officer now owns 601,253 shares of the company's stock, valued at $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets increased its stake in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. SG Americas Securities LLC acquired a new position in OptimizeRx during the fourth quarter worth about $51,000. Quest Partners LLC increased its holdings in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.